Browse News
Filter News
Found 808,890 articles
-
Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia
4/23/2024
Positive results from the LUNA 3 phase 3 study demonstrated that rilzabrutinib 400 mg twice daily orally achieved the primary endpoint of durable platelet response in adult patients with persistent or chronic immune thrombocytopenia.
-
ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
4/23/2024
ImmunityBio, Inc., an immunotherapy company, announced that the U.S. Food and Drug Administration has approved ANKTIVA plus Bacillus Calmette-Guérin for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors.
-
Brise Pharmaceuticals Raises nearly $20M in Series Pre-A and Pre-A+ Financing
4/23/2024
Brise Pharmaceuticals Co., LTD., a pioneering company specializing in innovative treatments for acute and chronic pain, has recently completed Pre-A and Pre-A+ financing with a total of approximately $20 million.
-
Vertex and TreeFrog Therapeutics Announce Licensing Agreement and Collaboration to Optimize Production of Vertex's Cell Therapies for Type 1 Diabetes
4/23/2024
Vertex Pharmaceuticals Incorporated and TreeFrog Therapeutics announced that Vertex has obtained an exclusive license to TreeFrog's proprietary cell manufacturing technology, C-StemTM, to optimize production of Vertex's cell therapies for type 1 diabetes.
-
PharmAbcine's U.S. Subsidiary, Wincal Biopharm, to Present Preclinical Data from its Proprietary OPC Platform Targeting Ocular Diseases at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2024
4/23/2024
PharmAbcine, Inc. announced that the Company's U.S. subsidiary, Wincal Biopharm, Inc., will present preclinical findings on its innovative ocular drug delivery platform at the upcoming conference, Association for Research in Vision and Ophthalmology, the world's largest ophthalmology conference which will be held from May 5th to 9th, 2024 in Seattle, WA, United States.
-
Ipsen is looking to deepen its expertise in movement disorders in a research collaboration with Skyhawk Therapeutics to develop small molecule drugs for RNA targets in neurological diseases.
-
Boehringer Ingelheim is paying $35 million in upfront and near-term fees to work with Ochre Bio to identify and validate regenerative targets for metabolic dysfunction-associated steatohepatitis and other chronic liver diseases.
-
Bristol Myers Squibb will be using Cellares’ Cell Shuttles, an automated production system capable of producing multiple cell therapies simultaneously, to potentially improve turnaround time to support the pharma’s CAR T cell therapies.
-
Drugmakers, including the genetic testing company 23andMe, are using novel approaches to stimulate NK cells’ intrinsic ability to recognize and kill tumor cells.
-
A one-time treatment for Parkinson’s disease could be a ‘market changer,’ experts told BioSpace, adding that cell therapies could limit the adverse effects seen with current drugs.
-
From gene-corrected cell therapies to a new CAR-T, the cell and gene therapy space looks to expand its reach into the market.
-
Follow along as BioSpace keeps you up-to-date on the latest pharma and biotech layoffs.
-
The FDA will close out April with five target action dates around indications that include pediatric seizures and a neurological cancer in children.
-
While Madrigal Pharmaceuticals secured the first FDA drug approval for metabolic dysfunction–associated steatohepatitis, Akero Therapeutics is developing what may serve as a viable alternative treatment for precirrhotic disease.
-
Bolstered by its portfolio of “revolutionary” therapies, AbbVie remains the top pharma company in the immunology space, according to a new survey of doctors by ZoomRx.
-
Following an investigation regarding antitrust practices against Pharmacosmos’ Monofer, CSL Vifor has proposed a sweeping multi-channel communication campaign designed to reverse allegedly misleading messages about its rival.
-
As AbbVie and NeuroDerm race toward potential U.S. approvals later this year, the companies presented strong data at last week’s American Academy of Neurology 2024 annual meeting for their respective continuous subcutaneous levodopa infusions.
-
QT Imaging Holdings (Nasdaq: QTI) to Ring The Nasdaq Stock Market Opening Bell
4/22/2024
QT Imaging Holdings, Inc., a medical device company engaged in research, development, and commercialization of innovative body imaging systems, is proud to announce the Opening Bell Ceremony at the Nasdaq MarketSite in Times Square.
-
Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024
4/22/2024
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company developing novel fatty acid synthase inhibitors designed to target dysfunctional metabolic and fibrotic pathways, announced it will host a virtual investor and analyst day on Friday, May 3, 2024 at 12:30 PM ET.
-
OraSure to Announce First Quarter 2024 Financial Results and Host Earnings Call on May 8th
4/22/2024
OraSure Technologies, Inc. has scheduled its regular earnings conference call covering first quarter 2024 financial results and certain business developments for 4:45 p.m. ET on Wednesday, May 8, 2024.